Alpha Tau Medical Ltd DRTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
-
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
-
Alpha Tau to Participate in October Investor Conferences
-
Alpha Tau to Participate in September Investor Conferences
-
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
-
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
-
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
-
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 92.48M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 121
- Website
- https://www.alphatau.com
Valuation
|
Metric
|
DRTS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 28.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DRTS
|
|---|---|
Quick Ratio | 10.66 |
Current Ratio | 11.09 |
Interest Coverage | — |
Quick Ratio
DRTS
Profitability
|
Metric
|
DRTS
|
|---|---|
Return on Assets (Normalized) | −43.99% |
Return on Equity (Normalized) | −69.99% |
Return on Invested Capital (Normalized) | −61.64% |
Return on Assets
DRTS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|P!hR@M | LOCK|!Bn^ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^?lr!D | LOCK|Pfft | $84B | |||
| Moderna Inc
MRNA
| LOCK|$><@b! | LOCK|qG> | $83B | |||
| argenx SE ADR
ARGX
| LOCK|#M&szr | LOCK|jhY | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|j>#WQ& | LOCK|s$X | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&Q#S^%c | LOCK|T!g# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>C#k&$$K | LOCK|lgL@ | $29B | |||
| Incyte Corp
INCY
| LOCK|@n>N#r | LOCK|xJ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|&P#B#hJ | LOCK|#Pr | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$Z^pRL | LOCK|rn | $14B |
United States